1. Allred DC, O'Connell P, Fuqua SA (1993) Biomarkers in early breast neoplasia. J Cell Biochem 17G(Suppl): 125–131
2. Alshafie GA, Abou-Issa HM, Seibert K, Harris RE (2000) Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol Rep 7: 1377–1381
3. Birner P, Oberhuber G, Stani J, Reithofer C, Samonigg H, Hausmaninger H, Kubista E, Kwasny W, Kandioler-Eckersberger D, Gnant M, Jakesz R (2001) Evaluation of the United States Food and Drug Administration – approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 7: 1669–1675
4. Bobrow LG, Happerfield LC, Gregory WM, Millis RR (1995) Ductal carcinoma in situ: assessment of necrosis and nuclear morphology and their association with biological markers. J Pathol 176: 333–341
5. Boland GP, Chan KC, Knox WF, Roberts SA, Bundred NJ (2003a) Value of the Van Nuys Prognostic Index in prediction of recurrence of ductal carcinoma in situ after breast-conserving surgery. Br J Surg 90: 426–432